Search Results
Your search for ,WHo matches 20203 pages
Showing 2701 - 2750Expert Point of View: Michiel S. Van der Heijden, MD, PhD
Formal discussant of the CheckMate 274 trial, Michiel S. Van der Heijden, MD, PhD, of the Netherlands Cancer Institute, said it is an “important” study. “In looking at these results, one should consider the goal of adjuvant therapy in this setting. Is overtreatment of patients cured by surgery...
Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment and Overall Survival in Older Patients With Cancer
In a study reported in the Journal of Clinical Oncology, Eng et al found that exposure to antibiotics within 1 year of starting immune checkpoint inhibitor therapy was associated with poorer survival among patients with cancer who were aged 65 years and older. Study Details The population-based...
CheckMate 274: Continued Disease-Free Survival Benefits With Adjuvant Nivolumab in High-Risk Urothelial Carcinoma
With longer-term follow-up, adjuvant nivolumab continued to demonstrate improved disease-free survival, non–urothelial tract recurrence–free survival, and distant metastasis–free survival vs placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after surgery,...
Cancer Stage and Receptor Status May Indicate Risk of Disease Recurrence in Breast Cancer Survivors
Investigators have found that in breast cancer survivors, the cancer’s stage and receptor status may help clinicians predict whether and when cancer might recur after initial treatment, according to a new study published by Neuman et al in Cancer. Study Methods and Results In the new study, the...
Fewer Cases of Melanoma and Extracutaneous Malignancies Detected Among Patients With Atopic Diseases
Researchers have found that patients with a history of atopic diseases may be less likely to develop melanoma than patients with a history of nonatopic diseases, according to a new study published by Komulainen et al in Melanoma Research. The findings also revealed that patients with atopic...
Early Intervention for Steroid-Refractory Chronic Graft-vs-Host Disease
This is Part 2 of Clinical Considerations in Chronic Graft-vs-Host Disease, a two-part video roundtable series. In this video, Dr. Yi-Bin Chen and Dr. Mitchell E. Horwitz discuss the case of a 65-year-old woman with inversion 16 acute myeloid leukemia who is in second complete remission. She...
Early Detection of Chronic Graft-vs-Host Disease
This is Part 1 of Clinical Considerations in Chronic Graft-vs-Host Disease, a two-part video roundtable series. In this video, Dr. Yi-Bin Chen and Dr. Mitchell E. Horwitz discuss the case of a 55-year-old man with FLT3-ITD–mutated acute myeloid leukemia in first complete remission who received a...
Myelofibrosis-Related Anemia
This is Part 2 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. In this video, Dr. Srden Verstovsek and Dr. Abdulraheem Yacoub discuss the management of patients with anemia as a presenting symptom of myelofibrosis. The patient is a 68-year-old woman who...
PSA Level at Time of Salvage Radiation Therapy After Radical Prostatectomy and Risk of All-Cause Mortality
In a study reported in the Journal of Clinical Oncology, Derya Tilki, MD, and colleagues identified a prostate-specific antigen (PSA) level cutpoint, above which initiation of salvage radiation therapy after radical prostatectomy was associated with an increased risk of all-cause mortality in...
Depression May Be Linked to Higher Levels of Inflammation, Poorer Outcomes in Patients With Lung Cancer
Patients with lung cancer who have moderate to severe depression may be two to three times more likely to have inflammation levels that predict poor survival rates, according to a new study published by Andersen et al in PLOS One. The findings may help explain why a substantial portion of patients...
Studies Focusing on Age- and Race-Related Disparities in Multiple Myeloma and Sickle Cell Disease
Research that addresses the compounding effects of age and race/ethnicity on access to quality health care and patient-centered outcomes such as physical function, frailty, and survival continues to be an emerging area of inquiry in hematology. Accordingly, novel research employing qualitative and...
Researchers Find New Genetic Risk Factors in Large Study of Prostate Cancer in Black Patients
Researchers have identified nine new genetic variants that may increase the risk of developing prostate cancer in Black patients, according to a novel study published by Chen et al in European Urology. The investigators also found that genetic differences may help determine which patients are most...
Neoadjuvant Plus Adjuvant vs Adjuvant Pembrolizumab in Advanced Melanoma
In the phase II SWOG Cancer Research Network S1801 trial reported in The New England Journal of Medicine, Sapna P. Patel, MD, and colleagues found that neoadjuvant plus adjuvant pembrolizumab significantly improved event-free survival vs adjuvant pembrolizumab alone in patients with stage IIIB to...
Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma: 5-Year Results of the ZUMA-1 Trial
As reported in the journal Blood by Sattva S. Neelapu, MD, and colleagues, 5-year outcomes from the the phase II ZUMA-1 trial showed that axicabtagene ciloleucel was associated with maintained response in one-third of patients with refractory large B-cell lymphoma. The estimated 5-year overall...
First-Line Pembrolizumab in Older Patients With dMMR Metastatic Colorectal Cancer
In a retrospective cohort study reported in JAMA Network Open, Saberzadeh-Ardestani et al found that first-line pembrolizumab was associated with clinically significant prolongation of survival outcomes in mostly older patients with mismatch repair–deficient (dMMR) metastatic colorectal cancer....
Access to Paid Sick Leave May Result in More Cancer Screenings
More individuals may undergo cancer screenings when employers are mandated to provide paid sick leave, according to a new study published by Callison et al in The New England Journal of Medicine. Researchers found that breast cancer screening rates increased up to 4% and colorectal cancer...
Black Women at High Risk of Breast Cancer May Face Obstacles in Receiving Preventive Care
Black women at high risk of developing breast cancer may face a variety of obstacles keeping them from receiving preventive care that could increase their chances of survival if they did develop the disease, according to a new study published by Padamsee et al in PLOS One. The new findings provide...
Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Patients With Cancer
In an analysis reported in JACC: CardioOncology, Zhu et al found that in the United States, Black patients with cancer were at increased risk of all-cause mortality and cardiovascular (CVD) mortality compared with White patients, and that White patients were at increased risk of both outcomes...
Prognosis of HER2-Low vs HER2-Negative Breast Cancer
In an analysis of National Cancer Database data reported in JAMA Oncology, Peiffer et al found “minimal prognostic differences” between HER2-low vs HER2-negative breast cancer, with the findings not supporting classification of HER2-low disease as a distinct disease subtype. Study Details The...
How Patient Navigation Programs Are Helping Drive Equitable Care for Patients With Cancer and Improve Outcomes
Although patient navigation is increasingly recognized as an important component in the delivery of patient-centered cancer care, the service is not universally available across all cancer programs in the United States, often because of the concerns of extra cost without tangible financial...
Updates From City of Hope on Renal Cell, Prostate, and Urothelial Cancers
Sumanta K. Pal, MD, introduces his City of Hope colleagues, Hedyeh Ebrahimi, MD, MPH, who discusses the prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma, and Daniela Castro, MSc, who discusses expanding eligibility criteria in kidney, prostate,...
American Cancer Society Data Show Colorectal Cancer Rates Are Rising in Younger Adults and Shifting to More Advanced Disease in People of All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall, and is the leading cause of death in ...
Association of Baseline and Subsequent Cardiovascular Health Metrics With Risk for Incident Cancers
In an analysis from the French GAZEL study reported in JACC: CardioOncology, Van Sloten et al found that better cardiovascular health scores at baseline and improvement in scores over 7 years were associated with a reduced risk of incident cancers. As stated by the investigators, “The commonality...
Addition of Pembrolizumab to Pemetrexed/Platinum in the First-Line Treatment of Metastatic Nonsquamous NSCLC: 5-Year Outcomes in the KEYNOTE-189 Study
As reported in the Journal of Clinical Oncology by Marina C. Garassino, MD, and colleagues, 5-year follow-up in the phase III KEYNOTE-189 trial has shown maintained progression-free and overall survival benefits with the addition of pembrolizumab to pemetrexed and platinum chemotherapy in the...
Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients With Non–Muscle-Invasive Bladder Cancer Amid BCG Shortage
Researchers have found that a safe, inexpensive chemotherapy combination may be better tolerated and more effective at preventing high-grade recurrence in patients with non–muscle-invasive bladder cancer than the standard-of-care bacillus Calmette-Guérin (BCG), according to a novel study published...
Hospital Surgical Volume May Impact Survival in Patients With Pancreatic Cancer Whose Minimally Invasive Surgery Is Converted to an Open Procedure
Patients with pancreatic ductal adenocarcinoma whose pancreatoduodenectomy is converted to an open (CTO) procedure from a minimally invasive procedure as a result of complications may fare better at institutions that perform more minimally invasive pancreatic cancer surgeries annually, according to ...
De-escalated Neoadjuvant T-DM1 With or Without ET vs Trastuzumab With ET in Hormone Receptor–Positive/HER2-Positive Early Breast Cancer
As reported in the Journal of Clinical Oncology by Nadia Harbeck, MD, PhD, and colleagues, 5-year follow-up from the phase II WSG-ADAPT-TP trial indicated that pathologic complete response (pCR) was associated with better outcomes irrespective of receipt of adjuvant chemotherapy among patients with ...
Immunotherapy Costs May Drive Increase in Medicare Spending for Outpatient End-of-Life Cancer Care
Researchers have discovered that recent increases in Medicare spending on outpatient end-of-life cancer care may have been driven almost entirely by costs associated with immunotherapy, which is given to fewer than one in five patients, according to a new study published by Mantz et al in the...
Combination Abatacept, Ruxolitinib, and/or Mechanical Ventilation May Decrease Mortality in Patients With Immune Checkpoint Inhibitor–Associated Cardiotoxicity
Although immune checkpoint inhibitors have substantially improved clinical outcomes in many cancer types, they have also been found to induce immune-related adverse events, including myocarditis, in about 1% of patients receiving the agents, which can lead to a mortality rate of up to 50%. Current...
Prevalence of High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Patients With BRCA1/2 Pathogenic Variants
In a Dutch study reported in the Journal of Clinical Oncology, Stroot et al identified the prevalence of high-grade serous carcinoma at risk-reducing salpingo-oophorectomy in asymptomatic BRCA1/2 pathogenic variant carriers. Study Details The study included asymptomatic BRCA1/2 pathogenic variant...
Michael B. Atkins, MD, on Renal Cell Carcinoma: Phase II Findings on Nivolumab and Ipilimumab
Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the HCRN GU16-260-Cohort A study of patients with previously untreated advanced clear cell renal cell carcinoma who received nivolumab and salvage nivolumab plus ipilimumab....
Mediterranean Diet and Immune Checkpoint Blockade Outcomes in Advanced Melanoma
In the PRIMM study reported in JAMA Oncology, Bolte et al found that consumption of a Mediterranean diet was associated with a high probability of objective response and 12-month progression-free survival among patients receiving immune checkpoint blockade treatment for advanced melanoma. As stated ...
Association of Immune-Related Adverse Events With Overall Survival in Patients Receiving Atezolizumab-Containing Therapy for Metastatic Nonsquamous NSCLC
In a pooled analysis reported in JAMA Oncology, Mark A. Socinski, MD, and colleagues found that patients with nonsquamous non–small cell lung cancer (NSCLC) receiving atezolizumab who had grade 1 or 2 immune-related adverse events in clinical trials had improved overall survival vs those with no...
Remote Interventions to Improve Uptake of Cancer Genetic Risk Assessment in Patients With Ovarian Cancer or High-Risk Breast Cancer
In a study reported in the Journal of Clinical Oncology, Anita Y. Kinney, PhD, RN, and colleagues found that a phone-based tailored risk counseling and navigation intervention resulted in a higher proportion of patients with ovarian or high-risk breast cancers receiving cancer genetic risk...
Millions of U.S. Individuals May Have Missed Cancer Screenings During Second Year of COVID-19 Pandemic
Investigators have found that millions of individuals in the United States continued to miss critical cancer screening tests during the second year of the COVID-19 pandemic, according to a new study published by Star et al in the Journal of Clinical Oncology. Compared with 2019 levels, individuals...
New Study Demonstrates Inferior Vena Cava Filters May Be Safe and Effective Way to Prevent Venous Thromboembolism
Researchers have discovered that few adverse events may be associated with the use of inferior vena cava filters to help prevent deep vein thrombosis from developing into pulmonary embolisms, according to a new study jointly published by Johnson et al in the Journal of Vascular and Interventional...
Residual Nonretroperitoneal Disease After Chemotherapy for Nonseminomatous Germ Cell Tumors
In a single-institution study reported in the Journal of Clinical Oncology, King et al identified the prevalence of teratoma and active germ cell tumor in patients with residual nonretroperitoneal disease following chemotherapy for advanced nonseminomatous germ cell tumors. As stated by the...
Andrea Necchi, MD, on Bladder Cancer: Phase II Results With Pembrolizumab Monotherapy
Andrea Necchi, MD, of Italy’s Vita-Salute San Raffaele University and the IRCCS San Raffaele Hospital and Scientific Institute, discusses new data from the KEYNOTE-057 trial on a novel systemic therapy for papillary high-risk non–muscle-invasive bladder cancer. The findings suggest that patients...
Urologic Oncologist Hyung Kim, MD, Named Chair of Cedars-Sinai Department of Urology
Cedars-Sinai has appointed urologic oncologist, surgeon, and research investigator Hyung Kim, MD, as the inaugural Chair of the newly established Department of Urology. “Dr. Kim is an outstanding clinical and academic leader who will strategically steer our urology enterprise,” said Shlomo Melmed, ...
ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreaK100, Other Trials
ASCO has updated its living guidelines for therapy for stage IV non–small cell lung cancer (NSCLC) with and without driver alterations based on newly available evidence in the field.1,2 “Living guidelines are becoming more important as the field of oncology expands and developments occur more...
ASCO Endorses CAP Guideline to Better Define Who Benefits From Immune Checkpoint Inhibitor Therapy
ASCO has endorsed a new guideline from the College of American Pathologists (CAP) on the use of mismatch repair (MMR) and microsatellite instability (MSI) testing, which could help oncologists more accurately identify patients who may be suitable candidates for immune checkpoint inhibitor ...
Expert Point of View: Adam M. Brufsky, MD
Commenting on the study from Tata Memorial Centre for The ASCO Post, Adam M. Brufsky, MD, Professor of Medicine, Associate Chief of the Division of Hematology/Oncology and Co-Director of the Comprehensive Breast Cancer Center at the University of Pittsburgh School of Medicine, noted that the...
Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Carboplatin Adds Benefit, New Study Shows
In a phase III randomized trial conducted in India, the addition of weekly carboplatin to standard taxane/anthracycline–based neoadjuvant chemotherapy improved pathologic complete response rates, event-free survival, and overall survival in patients with triple-negative breast cancer patients aged...
Expert Point of View: Breelyn A. Wilky, MD
Discussant of the INTRIGUE abstract, Breelyn A. Wilky, MD, Director of Sarcoma Medical Oncology, Deputy Associate Director for Clinical Research, University of Colorado, Aurora, called the data presented “compelling evidence of the power of ctDNA [circulating tumor DNA] to identify predictive...
INTRIGUE Study: Circulating Tumor DNA Analysis May Predict Optimal Treatment of Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help to predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented during the ASCO Plenary Series: January 2023 Session.1 Exploratory analysis of the phase...
Neo-AEGIS Trial Finds Two Approaches Comparable in Treating Advanced Esophageal Cancer
A randomized trial that sought to determine the optimal approach to treating locally advanced esophageal or gastroesophageal junction cancer has ended in “equipoise,” according to the investigators of the Neo-AEGIS trial. In a study reported at the 2023 ASCO GI Cancers Symposium, perioperative...
Expert Point of View: Laura Goff, MD, MSCI
Invited discussant Laura Goff, MD, MSCI, Associate Professor of Medicine and Executive Medical Director for the Cancer Patient Care Center at Vanderbilt-Ingram Cancer Center, Nashville, said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic...
First-Line NALIRIFOX Improves Survival in Metastatic Pancreatic Cancer
In the phase III NAPOLI-3 trial in previously untreated patients with metastatic pancreatic cancer, the NALIRIFOX regimen significantly improved overall survival and progression-free survival over nab-paclitaxel plus gemcitabine.1 NALIRIFOX, which contains liposomal irinotecan, fluorouracil,...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Recommendations for Promoting Sexual and Gender Minority Inclusion in Oncology Care
Approximately 10% of adults in the United States self-report being members of sexual and gender minorities (SGMs), which means that most oncologists will treat SGM patients in their practice. Here are some suggestions on how clinicians and oncology institutions can help SGM patients feel safe and...
